Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial

The Lancet

Volumn 380, Issue 9843, 2012, Pages 738-746

  Papp, Kim ^a   Cather, Jennifer C ^b   Rosoph, Les ^c   Sofen, Howard ^d   Langley, Richard G ^e   Matheson, Robert T ^f   Hu, Chiachi ^g   Day, Robert M ^g  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b Modern Research Associates   (United States)

^c North Bay Dermatology Centre   (Canada)

^d Dermatology Research Associates   (United States)

^e DALHOUSIE UNIVERSITY   (Canada)

^f OREGON MEDICAL RESEARCH CENTER   (United States)

^g CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ELECTROCARDIOGRAPHY; FEMALE; GASTROENTERITIS; HEADACHE; HEMATOLOGY; HUMAN; IMMUNOLOGY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; TENSION HEADACHE; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; VIRAL UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 84865373941     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60642-4     Document Type: Article

References (28)

1. Saurat JH, Guerin A, Yu AP, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010; 220: 128-37.
2. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008; 67: 855-59. (Pubitemid 351829388)
3. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation, 2011.
4. Rheumatrex [package insert]. Fort Lee, NJ: DAVA Pharmaceuticals, 2009.
5. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 370-79.
6. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74. (Pubitemid 41443403)
7. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-26. (Pubitemid 46955730)
8. Brunasso AM, Puntoni M, Salvini C, et al. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients. Acta Derm Venereol 2011; 91: 44-49.
9. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
10. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 2004; 84: 137-67. (Pubitemid 38049878)
11. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005; 10: 1503-19. (Pubitemid 41527193)
12. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010; 159: 842-55.
13. McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010; 12: 1-11.
14. Heystek HC, Thierry A-C, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 2003; 15: 827-35. (Pubitemid 36827071)
15. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 2007; 178: 4820-31. (Pubitemid 46595264)
16. Tenor H, Hedbom E, Hauselmann HJ, Schudt C, Hatzelmann A. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes\functional importance of phosphodiesterase 4. Br J Pharmacol 2002; 135: 609-18. (Pubitemid 34177638)
17. Wu A, Scheffler M. First-time-in-man, safety/tolerability and pharmacokinetics of ascending oral doses of apremilast (APR) in healthy subjects (HS). J Invest Dermatol 2011; 131: S86.
18. Hoffmann M, Kumar G, Schafer P, et al. Disposition, metabolism and mass balance of [¹4C]apremilast following oral administration. J Invest Dermatol 2011; 131: S89.
19. Nissel J, Wu A, Laille E, et al. Lack of pharmacokinetic interaction between oral apremilast and methotrexate in rheumatoid arthritis and psoriatic arthritis patients. Annual Congress of the European League Against Rheumatism; London, UK; May 25-28, 2011. EULAR abstract AB0382.
20. Wu A, Dvorchik B, Cabell C, et al. Double-blind, randomized, multiple-dose, crossover, four-treatment, four-period, four-sequence study to investigate the effects of apremilast on the QT interval in healthy male subjects. Annual Meeting of the American College of Clinical Pharmacy; Austin, TX, USA; Oct 17-20, 2010.
21. Wu A, Rohane P, Patin J, Laskin O. Effect of ketoconazole on the pharmacokinetics of CC-10004 in healthy subjects. Annual Meeting of the American College of Clinical Pharmacology; Cambridge, MA, USA; Sept 17-19, 2006.
22. Papp K, Zeldis JB, Rohane P, Thaci D. A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-1004 in subjects with moderate to severe psoriasis. J Am Acad Dermatol 2008; 58: AB3.
23. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008; 24: 1529-38. (Pubitemid 351741586)
24. Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco, CA: Holden-Day, 1975.
25. Van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Institute. Hague: International Statistical Institute, 1960: 351-61.
26. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16. (Pubitemid 24194579)
27. Kini SP, Delong LK, Veledar E, Kenzie-Brown AM, Schaufele M, Chen SC. The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol 2011; 147: 1153-56.
28. Schett G, Wollenhaupt J, Papp K, et al. Apremilast is active in the treatment of psoriatic arthritis (Ps A). Arthritis Rheum 2009; 60 (suppl 10): 1258.